NASDAQ: ACAD · Biotechnology
Over the past week, Acadia Pharmaceuticals (ACAD) racked up about 28 mentions across Reddit, X and news, and the read is an Adanos Hold. The crowd averages 49% bullish but is sharply divided: X runs 63% bullish while News sits at just 35%. Wall Street is more constructive, with 16 of 21 analysts rating ACAD a buy.
There is little buzz around ACAD this week and little agreement on direction, which is why it reads as a Hold.
Wall Street’s 76% buy share sits next to a crowd that ranges from News at 35% to X at 63%. No other tracker puts the two side by side.
21 analysts have weighed in: a Strong Buy consensus: 16 buy calls against 1 sell, with an average 12-month price target of $33.32.
The Adanos signal blends each source’s bullish ratio, source breadth, buzz intensity and 3-day momentum. This week bullish sits right on the neutral line, momentum is cooling and the 2 sources disagree sharply, so the read is Hold rather than a clear buy or sell.
Analysts sit 27 points above the crowd average of 49%, the professionals are more constructive than retail. The split is inside the crowd: X reads 63% bullish while News sits at 35%, a 28-point spread that single-source trackers miss.
Over the 30-day window, Acadia Pharmaceuticals (ACAD) buzz held subdued around 37.3 while the price drifted down 29.0% across the period. The chart tracks how social and news attention moved against end-of-day price. Average daily trading volume across the displayed trading days is 1.9M shares. Updated Sep 26, 2026. Over the last 7 trading days, ACAD lost 24.7%. Buzz activity in the recent week averaged 33.3 and was variable, swinging between 18.2 and 44.3. Recent volume is running above the 30-day average, suggesting heightened trading interest. Daily crowd sentiment leaned bullish on 4 of the 6 days with directional mentions, shown as the green, grey and red breakdown bars below the chart.
Signal metrics use the latest 7 days; contributor and breadth context uses the 30-day chart window.
No Reddit data for this stock this week.
No Polymarket data for this stock this week.
Query sentiment for ACAD and 2110+ stocks from your terminal. Filter by source, timeframe and signal strength.
View CLIEmbed live ACAD sentiment on your own site with drop-in web components.
View WidgetsThis week’s sentiment from Adanos, with fundamentals and analyst consensus. A quick-reference snapshot for Sep 26, 2026.
| Adanos signal | Hold |
|---|---|
| Analyst consensus | Strong Buy (16 / 4 / 1) |
| Crowd bullish (7d) | 49% |
| Avg price target | $33.32 |
| Most bullish source | X, 63% |
| Most bearish source | News, 35% |
| Sentiment spread | 28 pts |
| Mentions (7d) | 28 |
| Market cap | $3.82B |
| P/E · Forward P/E | 11.4 · 25.2 |
| EPS · Beta | $1.95 · 0.9 |
| Revenue (TTM) | $1.14B · 33% margin |
| Industry | Biotechnology |
Based on aggregated sentiment from X and News sources, Acadia Pharmaceuticals (ACAD) currently carries an Adanos hold signal with 57/100 conviction. The current cross-source average reads 49% bullish across 2 active sources. Those sources contribute 28 tracked mentions over the last 7 days. This is a sentiment-based reading, not financial advice.
The crowd reads split on Acadia Pharmaceuticals (ACAD), averaging 49% bullish across 2 tracked sources over the last 7 days. The two ends of the range are X at 63% bullish and News at 35%, a 28-point spread. On the professional side, 16 of 21 analysts rate ACAD a buy.
Of the 21 analysts covering Acadia Pharmaceuticals (ACAD), 16 rate it a buy, 4 a hold and 1 a sell, for a strong buy consensus. The average price target is $33.32. That puts the street ahead of the crowd, which averages 49% bullish.
Acadia Pharmaceuticals (ACAD)'s cross-source average is mixed at 49% bullish. Source readings are split: 1 source leans bullish and 1 source leans bearish. X reads 63% bullish and news coverage is the most negative at 35% bullish. The combined signal points to broad mixed pressure with 57/100 conviction.
The cross-source average is mixed for Acadia Pharmaceuticals (ACAD) at 49% bullish. Source readings are split: 1 source leans bullish and 1 source leans bearish. The most bearish reading is news at 35% bullish. 3-day activity momentum is falling across News. The hold signal carries 57/100 conviction.
News is the dominant discussion channel with 20 mentions (71% of total volume). X contributes 8 mentions. The cross-source average is mixed at 49% bullish. Source readings are split: 1 source leans bullish and 1 source leans bearish.
The Adanos signal blends bullish ratio, buzz score, source breadth and 3-day activity momentum into a single buy/sell reading. ACAD's hold signal at 57/100 conviction reflects a mixed cross-source average at 49% bullish. Source readings are split: 1 source leans bullish and 1 source leans bearish. It is a research shortcut, not financial advice.
The ACAD sentiment page is regenerated from the latest 7-day tracking window at each build. Data reflects the most recent Reddit posts, tweets and news articles available in the current publishing cycle.
Peers are ranked first by matching the Hold signal, then by the closest bullish ratio. Discussion activity breaks any remaining ties.
Every data point on this page comes from the Adanos sentiment APIs. Get a free API key and start querying Reddit, X, News and Polymarket sentiment programmatically.
Get Free API Key